The TGA has approved atezolizumab (Tecentriq) in combination with bevacizumab (Avastin), and chemotherapy (paclitaxel and carboplatin), for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). The immunotherapy-chemotherapy combination is indicated for patients with EGFR mutant or ALK-positive NSCLC, after failure of appropriate targeted therapies. The new approval was based ...
Atezolizumab-based combination gets first line approval for metastatic NSCLC
By Michael Woodhead
12 Jul 2019